Application of internal limiting membrane peeling for the treatment of diabetic macular edema

doi:10.3877/cma.j.issn.2095-2007.2017.04.006

Abstract

Abstract:

The internal limiting membrane as the inner structure of retina closely attached to vitreous, serves as an interface between the vitreous and retina with important biomechanical and physiological role. internal limiting membrane contributes to tangential traction and acts as a platform on which glial cells proliferate. internal limiting membrane plays a crucial part in the occurrence and development of Diabetic Macular Edema(DME). Thus, pars plana vitrectomy(PPV) with internal limiting membrane peeling could be an effective surgical treatment for tractional or non-tractional DME and an alternative therapy for diffuse and refractory DME.We highlight the internal limiting membrane’s role in DME pathogenesis and review the present situation and advances in treatment of DME.We also show the anatomical and functional findings after internal limiting membrane peeling in DME patients and discuss the benifical and adverse effects associated with internal limiting membrane peeling and optimal time for operation.

Key words: Internal limiting membrane peeling, Diabteic macular edema, Pars plana vitrectomy

Yimeng Sun, Kai Ma. Application of internal limiting membrane peeling for the treatment of diabetic macular edema[J]. Chinese Journal of Ophthalmologic Medicine(Electronic Edition), 2017, 07(04): 177-183.

/ / Recommend

Add to citation manager EndNote|Ris|BibTeX

URL: https://zhykyxzz.cma-cmc.com.cn/EN/10.3877/cma.j.issn.2095-2007.2017.04.006

https://zhykyxzz.cma-cmc.com.cn/EN/Y2017/V07/I04/177

References 81

[1]	Zheng Y, Lamoureux EL, Lavanya R, et al. Prevalence and Risk Factors of Diabetic Retinopathy in Migrant Indians in an Urbanized Society in Asia: The Singapore Indian Eye Study[J]. Ophthalmology, 2012, 119(10):2119-2124.
[2]	Petrella RJ, Blouin J, Davies B, et al. Prevalence, demographics and treatment characteristics of visual impairment due to diabetic macular edema in a representative canadian cohort[J]. Journal of Ophthalmology, 2012, 2012(7):159167.
[3]	Bhagat N, Grigorian RA, Tutela A, et al. Diabetic Macular Edema: Pathogenesis and Treatment[J]. Survey of Ophthalmology, 2009, 54(1):1-32.
[4]	ETDRS Group. Early photocoagulation for diabetic retinopathy. ETDRS report number 9[J]. Ophthalmology, 1991, 98(Suppl. 5):766-785.
[5]	Olk RJ. Modified grid argon (blue－creen) laser photocoagulation for diffuse diabetic macular edema. Long－term visual results[J]. Ophthalmology, 1986, 93(7):938-950.
[6]	Anna－Karin O, Anna D, Johan K, et al. VEGF receptor signalling in control of vascular function[J]. Nature Reviews Molecular Cell Biology, 2006, 7(5):359-371.
[7]	Antonetti DA, Barber AJ, Hollinger LA, et al. Vascular endothelial growth factor induces rapid phosphorylation of tight junction proteins occludin and zonula occluden 1. A potential mechanism for vascular permeability in diabetic retinopathy and tumors[J]. Journal of Biological Chemistry, 1999, 274(33):23463-23467.
[8]	Arevalo JF, Fromow－Guerra J, Quiroz－Mercado H, et al. Primary intravitreal bevacizumab (Avastin) for diabetic macular edema: results from the Pan－American Collaborative Retina Study Group at 6－month follow－up[J]. Ophthalmology, 2007, 114(4):743-750.
[9]	Mitchell P, Bandello F, Schmidt－Erfurth U, et al. The RESTORE Study : ranibizumab monotherapy or combined with laser versus laser monotherapy for diabetic macular edema[J]. Ophthalmology, 2011, 118(4):615-625.
[10]	Elman MJ, Bressler NM, Qin H, et al. Expanded 2－year follow－up of ranibizumab plus prompt or deferred laser or triamcinolone plus prompt laser for diabetic macular edema[J]. Ophthalmology, 2011, 118(4):609-614.
[11]	Kovarik JJ, Eller AW, Willard LA, et al. Prevalence of undiagnosed diabetic retinopathy among inpatients with diabetes: the diabetic retinopathy inpatient study (DRIPS)[J]. BMG Open Diabetes Research & Care, 2016, 4(1):e000164.
[12]	Solomon SD, Chew E, Duh EJ, et al. Diabetic Retinopathy: A Position Statement by the American Diabetes Association[J]. Diabetes Care, 2017, 40(3):412-418.
[13]	Martidis A, Duker JS, Greenberg PB, et al. Intravitreal triamcinolone for refractory diabetic macular edema[J]. Ophthalmology, 2002, 109(5):920-927.
[14]	Stefánsson E. Ocular oxygenation and the treatment of diabetic retinopathy[J]. Survey of Ophthalmology, 2006, 51(4):364-380.
[15]	Barile GR, Pachydaki SI, Tari SR, et al. The RAGE axis in early diabetic retinopathy[J]. Invest Ophthalmol Vis Sci, 2005, 46(8):2916-2924.
[16]	Harbour JW, SWE JR, Rubsamen PE, et al. Vitrectomy for diabetic macular edema associated with a thickened and taut posterior hyaloid membrane[J]. Am J Ophthalmol, 1996, 121(4):405-413.
[17]	Ikeda T, Sato KT, Hayashi Y. Vitrectomy for cystoid macular oedema with attached posterior hyaloid membrane in patients with diabetes[J]. Br J Ophthalmol, 1999, 83(1):12-14.
[18]	李洁，张喜梅，马涛. 内界膜剥除术在眼底疾病治疗中的应用[J]. 国际眼科纵览，2016,40(2):107-111.
[19]	Heegaard S, Jensen OA, Prause JU. Structure and composition of the inner limiting membrane of the retina. SEM on frozen resin－cracked and enzyme－digested retinas of Macaca mulatta[J]. Graefe's Archive for Clinical and Experimental Ophthalmology, 1986, 224(4):355-360.
[20]	Semeraro F, Morescalchi F, Duse S, et al. Current trends about inner limiting membrane peeling in surgery for epiretinal membranes[J]. Journal of Ophthalmology, 2015, 2015(12):671905.
[21]	辛晓蓉，巩天祥. 糖尿病视网膜表面膜细胞成分的研究[J]. 眼科新进展，2013,33(4):309-311.
[22]	Ferrara N. Role of vascular endothelial growth factor in regulation of physiological angiogenesis[J]. American Journal of Physiology Cell Physiology, 2001, 280(6):C1358.
[23]	Bonnin S, Sandali O, Bonnel S, et al. Vitrectomy with internal limiting membrane peeling for tractional and nontractional diabetic macular edema: long－term results of a comparative study[J]. Retina, 2015, 35(5):921-928.
[24]	Kelly NE, Wendel RT. Vitreous surgery for idiopathic macular holes: results of a pilot study[J]. Archives of Ophthalmology, 1991, 109(5):654-659.
[25]	Morris R, Kuhn F, Witherspoon CD, et al. Hemorrhagic macular cysts in terson′s syndrome and its implications for macular surgery[J]. Developments in Ophthalmology, 1997, 29:44-54.
[26]	Gandorfer A, Messmer EM, Ulbig MW, et al. Resolution of diabetic macular edema after surgical removal of the posterior hyaloid and the inner limiting membrane[J]. Retina, 2000, 20(20):126-133.
[27]	Nakajima T, Roggia MF, Noda Y, et al. Effect of internal limiting membrane peeling during vitrectomy for diabetic macular edema: systematic review and meta－analysis[J]. Retina, 2015, 35(9):1719-1725.
[28]	Romano V, Angi M, Scotti F, et al. Inflammation and macular oedema after pars plana vitrectomy[J]. Mediators of Inflammation, 2013, 2013(6):971758.
[29]	Mikhail M, Ali－Ridha A, Chorfi S, et al. Long－term outcomes of sutureless 25－G＋ pars－plana vitrectomy for the management of diabetic tractional retinal detachment[J]. Graefe's Archive for Clinical and Experimental Ophthalmology, 2017, 255(2):255-261.
[30]	Yang CM, Cheng YSF. Macular appearance after diabetic vitrectomy for fibrovascular proliferation: an optical coherence tomography study[J]. Acta Ophthalmologica, 2010, 88(2):193-198.
[31]	Schwatz SD, Alexander R, Hiscott P, et al. Recognition of vitreoschisis in proliferative diabetic retinopathy. A useful landmark in vitrectomy for diabetic traction retinal detachment[J]. Ophthalmology, 1996, 103(2):323-328.
[32]	Gandorfer A, Rohleder M, Kampik A. Epiretinal pathology of vitreomacular traction syndrome[J]. Bri J Ophthalmology, 2002, 86(8):902-909.
[33]	Matsumoto H, Yamanaka I, Hisatomi T, et al. Triamcinolone acetonide－assisted pars plana vitrectomy improves residual posterior vitreous hyaloid removal: ultrastructural analysis of the inner limiting membrane[J]. Retina. 2007, 27(2):174-179.
[34]	Chang P, Yang CC, Chen M, et al. Pars plana vitrectomy for diabetic fibrovascular proliferation with and without internal limiting membrane peeling.[J]. Eye, 2009, 23(4):960-965.
[35]	Berrocal MH, Acaba LA, Acaba A. Surgery for Diabetic Eye Complications[J]. Current Diabetes Reports, 2016, 16(10):99.
[36]	Rosenblatt BJ, Shah GK, Sharma S, et al. Pars plana vitrectomy with internal limiting membranectomy for refractory diabetic macular edema without a taut posterior hyaloid[J]. Graefe's Archive for Clinical and Experimental Ophthalmology, 2005, 243(1):20-25.
[37]	Yamamoto T, Akabane N, Takeuchi S. Vitrectomy for diabetic macular edema: the role of posterior vitreous detachment and epimacular membrane[J]. Am J Ophthalmol, 2001, 132(3):369-377.
[38]	Stolba U, Binder S, Gruber D, et al. Vitrectomy for persistent diffuse diabetic macular edema[J]. Am J Ophthalmol, 2005, 140(2):295-301.
[39]	Kishi S, Demaria C, Shimizu K. Vitreous cortex remnants at the fovea after spontaneous vitreous detachment[J]. International Ophthalmology, 1986, 9(4):253-260.
[40]	Gandorfer A, Messmer EM, Ulbig MW, et al. Resolution of diabetic macular edema after surgical removal of the posterior hyaloid and the inner limiting membrane[J]. Retina, 2000, 20(20):126-133.
[41]	Dehghan MH, Salehipour M, Naghib J, et al. Pars plana vitrectomy with internal limiting membrane peeling for refractory diffuse diabetic macular edema[J]. Journal of Ophthalmic & Vision Research, 2010, 5(3):162-167.
[42]	Figueroa MS, Contreras I, Noval S. Surgical and anatomical outcomes of pars plana vitrectomy for diffuse nontractional diabetic macular edema[J]. Retina, 2008, 28(3):420-426.
[43]	Kimura T, Kiryu J, Nishiwaki H, et al. Efficacy of surgical removal of the internal limiting membrane in diabetic cystoid macular edema[J]. Retina, 2005, 25(4):454-461.
[44]	Ghassemi F, Bazvand F, Roohipoor R, et al. Outcomes of vitrectomy, membranectomy and internal limiting membrane peeling in patients with refractory diabetic macular edema and non－tractional epiretinal membrane[J]. Journal of Current Ophthalmology, 2016, 28(4):199-205.
[45]	Stefaniotou M, Aspiotis M, Kalogeropoulos C, et al. Vitrectomy results for diffuse diabetic macular edema with and without inner limiting membrane removal[J]. European Journal of Ophthalmology, 2004, 14(2):137-143.
[46]	Meena CMS, Valsa SMS, Sonia RJ, et al. Efficacy of internal limiting membrane remocal in recalcitrant diabitic macular oedema－comparative analysis of macular thickness by optical coherence tomography[J]. Kerala Journal of Ophthalmology, 2017, 19(3):259-265.
[47]	Liang DC, Yang CP, Lin DT, et al. Long－term results of Taiwan Pediatric Oncology Group studies 1997 and 2002 for childhood acute lymphoblastic leukemia[J]. Leukemia, 2010, 24(2):397-405.
[48]	Romano MR, Romano V, Vallejo－Garcia JL, et al. Macular hypotrophy after internal limiting membrane removal for diabetic macular edema[J]. Retina, 2014, 34(6):1182-1189.
[49]	Kitaoka T, Taniguchi H, Miyamura N, et al. Aquaporin expression of the internal limiting membrane in diabetic macular edema and idiopathic macular hole[J]. Invest Ophthalmol Vis Sci, 2003, 44(13):3075.
[50]	Rosenblatt BJ, Shah GK, Sharma S, et al. Pars plana vitrectomy with internal limiting membranectomy for refractory diabetic macular edema without a taut posterior hyaloid[J]. Graefe's Archive for Clinical and Experimental Ophthalmology, 2005, 243(1):20-25.
[51]	Sakamoto A, Nishijima K, Kita M, et al. Association between foveal photoreceptor status and visual acuity after resolution of diabetic macular edema by pars plana vitrectomy[J]. Graefe's Archive for Clinical and Experimental Ophthalmology, 2009, 247(10):1325-1330.
[52]	Aiello LM. Photocoagulation for diabetic macular edema[J]. Arch Ophthalmol, 1986, 104(8):1115-1116.
[53]	Cusick M, Chew EY, Chan CC, et al. Histopathology and regression of retinal hard exudates in diabetic retinopathy after reduction of elevated serum lipid levels[J]. Ophthalmology, 2003, 110(11):2126-2133.
[54]	Klein R, Klein BE, Moss SE, et al. The Wisconsin epidemiologic study of diabetic retinopathy. II. Prevalence and risk of diabetic retinopathy when age at diagnosis is less than 30 years[J]. Arch Ophthalmol, 1984, 102(4):520-526.
[55]	Massin P, Haouchine B, Gaudric A. Macular traction detachment and diabetic edema associated with posterior hyaloidal traction[J]. Am J Ophthalmol, 2001, 131(1):44-49.
[56]	Yamamoto T, Hitani K, Tsukahara I, et al. Early postoperative retinal thickness changes and complications after vitrectomy for diabetic macular edema[J]. Am J Ophthalmol, 2003, 135(1):14-19.
[57]	BH Jr. Macular hole surgery with and without internal limiting membrane peeling[J]. Archivos De La Sociedad Espaola De Oftalmología, 2000, 107(10):1938-1939.
[58]	Haritoglou C, Gandorfer A, Gass CA, et al. Indocyanine green－assisted peeling of the internal limiting membrane in macular hole surgery affects visual outcome: a clinicopathologic correlation[J]. Am J Ophthalmol, 2002, 136(6):1193-1194.
[59]	Da MA, Burk SE, Foster RE, et al. Long－term follow－up of indocyanine green－assisted peeling of the retinal internal limiting membrane during vitrectomy surgery for idiopathic macular hole repair[J]. Ophthalmology, 2004, 111(12):2246-2253.
[60]	Kadonosono K, Itoh N, Uchio E, et al. Staining of internal limiting membrane in macular hole surgery[J]. Archives of Ophthalmology, 2000, 118(8):1116-1118.
[61]	Gandorfer A, Haritoglou C, Gass CA, et al. Indocyanine green－assisted peeling of the internal limiting membrane may cause retinal damage[J]. Am J Ophthalmol, 2001, 132(3):431-433.
[62]	Burk SE, Da MA, Snyder ME, et al. Indocyanine green－assisted peeling of the retinal internal limiting membrane[J]. Ophthalmology, 2000, 107(11):2010-2014.
[63]	Mester V, Kuhn F. Internal limiting membrane removal in the management of full－thickness macular holes[J]. Am J Ophthalmol, 2000, 129(6):769-777.
[64]	Gandorfer A, Messmer EM, Ulbig MW, et al. Resolution of diabetic macular edema after surgical removal of the posterior hyaloid and the inner limiting membrane[J]. Retina, 2000, 20(20):126-133.
[65]	Stalmans P, Van LA, Parysvan GR. Indocyanine green－assisted peeling of the internal limiting membrane in macular hole surgery affects visual outcome: a clinicopathological correlation[J]. Am J Ophthalmol, 2003, 136(5):961-962.
[66]	Yoshimura K. Thylakoid membrane－bound ascorbate peroxidase is a limiting factor of antioxidative systems under photo－oxidative stress[J]. Plant Journal, 2002, 32(6):915-925.
[67]	Laulagnier K, Motta C, Hamdi S, et al. Mast cell－ and dendritic cell－derived exosomes display a specific lipid composition and an unusual membrane organization[J]. Biochemical Journal, 2004, 380(1):161-171.
[68]	Rehak J, Rehak M. Branch Retinal Vein Occlusion: Pathogenesis, Visual Prognosis, and Treatment Modalities[J]. Current Eye Research, 2008, 33(2):111-131.
[69]	Enaida H, Sakamoto T, Hisatomi T, et al. Morphological and functional damage of the retina caused by intravitreous indocyanine green in rat eyes[J]. Graefes Archive for Clinical & Experimental Ophthalmology, 2002, 240(3):209-213.
[70]	Smiddy WE, Feuer W, Cordahi G. Internal limiting membrane peeling in macular hole surgery[J]. Ophthalmology, 2001, 108(8):1471-1476.
[71]	Sippy BD, Engelbrecht NE, Hubbard GB, et al. Indocyanine green effect on cultured human retinal pigment epithelial cells: implication for macular hole surgery[J]. Am J Ophthalmol, 2001, 132(3):433-435.
[72]	Rizzo S, Genovesi－Ebert F, Murri S, et al. 25－gauge, sutureless vitrectomy and standard 20－gauge pars plana vitrectomy in idiopathic epiretinal membrane surgery: a comparative pilot study[J]. Graefes Archive for Clinical & Experimental Ophthalmology, 2006, 244(4):472-479.
[73]	Li K, Wong D, Hiscott P, et al. Trypan blue staining of internal limiting membrane and epiretinal membrane during vitrectomy: visual results and histopathological findings[J]. Bri J Ophthalmol, 2003, 87(2):216-219.
[74]	Park DW, Dugel PU, Garda J, et al. Macular pucker removal with and without internal limiting membrane peeling: pilot study[J]. Ophthalmology, 2003, 110(1):62-64.
[75]	Sutter EE, Tran D. The field topography of ERG components in man, I: the photopic luminance response[J]. Vision Research, 1992, 32(3):433-446.
[76]	Rohrschneider K, Bültmann S, Glück R, et al. Scanning laser ophthalmoscope fundus perimetry before and after laser photocoagulation for clinically significant diabetic macular edema[J]. Am J Ophthalmol, 2000, 129(1):27-32.
[77]	Sanders CR, Myers JK. Disease－Related Misassembly of Membrane Proteins[J]. Annual Review of Biophysics & Biomolecular Structure, 2004, 33(33):25-51.
[78]	Gass CA, Haritoglou C, Schaumberger M, et al. Functional outcome of macular hole surgery with and without indocyanine green－assisted peeling of the internal limiting membrane[J]. Graefes Archive for Clinical & Experimental Ophthalmology, 2003, 241(9):716-720.
[79]	Cuervo AM, Dice JF. Regulation of Lamp2a Levels in the Lysosomal Membrane[J]. Traffic, 2000, 1(7):570-583.
[80]	Enaida H, Hisatomi T, Hata Y, et al. Brilliant blue G selectively stains the internal limiting membrane, brilliant blue G－assisted membrane peeling[J]. Retina, 2006, 26(6):631-636.
[81]	Liang P, Huang X, Fan MZ, et al. Composition and distribution of internal resistance in three types of microbial fuel cells[J]. Applied Microbiology & Biotechnology, 2007, 77(3):551-558.

Please choose a citation manager

Content to export